Clinical Trial Update: Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin

View source ↗

Summary

This completed clinical trial monitors the incidence of pure red cell aplasia and antibodies to erythropoietin among participants receiving epoetin alfa or anot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Pure Red Cell Aplasia

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• Epogen (epoetin alfa)
• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Red-Cell Aplasia, Pure, Chronic Renal Failure | Status: COMPLETED